IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.421
EU - Europa 1.638
AS - Asia 302
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 2
Totale 7.372
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.408
UA - Ucraina 828
DE - Germania 292
FI - Finlandia 270
CN - Cina 259
IE - Irlanda 116
SE - Svezia 56
IT - Italia 41
TR - Turchia 39
GB - Regno Unito 19
CA - Canada 13
RU - Federazione Russa 12
EU - Europa 9
IN - India 2
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
FR - Francia 1
KR - Corea 1
LT - Lituania 1
MK - Macedonia 1
TW - Taiwan 1
Totale 7.372
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 632
Woodbridge 438
Wilmington 369
Ashburn 368
Seattle 340
Cambridge 329
Houston 313
Chandler 306
Dearborn 284
Beijing 140
Princeton 134
Dublin 116
Ann Arbor 115
San Diego 78
Izmir 39
Norwalk 32
Ogden 29
Kunming 22
Udine 22
Hefei 16
Nanjing 12
Des Moines 10
New York 10
Ottawa 10
Nanchang 9
Jinan 7
Boardman 6
Chengdu 6
Grafing 6
Guangzhou 6
Changsha 3
Fuzhou 3
Genova 3
Hebei 3
Shenyang 3
Toronto 3
Andover 2
Baotou 2
Chongqing 2
Hangzhou 2
Helsinki 2
Jiaxing 2
Jinhua 2
Milan 2
Saint Petersburg 2
Wenzhou 2
Zhengzhou 2
Azzano Decimo 1
Brescia 1
Changchun 1
Chennai 1
Codroipo 1
Cornigliano 1
Guiyang 1
Harbin 1
Irving 1
Kamyshin 1
Kaunas 1
Padova 1
Porto Alegre 1
Prilep 1
Redmond 1
Shaoxing 1
Simi Valley 1
Southampton 1
Taipei 1
Tappahannock 1
Trieste 1
Washington 1
Wuhan 1
Xian 1
Totale 5.202
Salva come PNG Salva come JPEG
Nome #
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 126
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 120
Taxane-induced nail changes: incidence, clinical presentation and outcome 115
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 91
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 90
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 90
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 89
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 86
Chemotherapy: which drug and when? 86
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 85
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 85
Irinotecan in combination with new agents 84
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 83
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 83
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 83
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 83
The potential role of Tomudex in the treatment of advanced colorectal cancer 81
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 81
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 81
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 80
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 80
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 80
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 79
Fatigue: a main component of anemia symptomatology 78
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 78
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 78
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 78
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 78
Urgent need for a new staging system in advanced colorectal cancer 77
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 76
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 75
Current controversies in the adjuvant therapy of colon cancer 74
Bevacizumab plus fluorouracil: the value of being part of a developing story 74
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 74
Optimal treatment of metastatic colorectal cancer 74
Determinants of sensitivity and resistance to fluoropyrimidines 73
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 73
Tamoxifen-induced total alopecia 73
How uniform are postgraduate training programs in medical oncology in the European Union? 72
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 72
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 72
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 72
Current strategies to reduce cisplatin toxicity 71
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 71
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 71
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 71
Highlights from the 2008 Gastrointestinal Cancers Symposium 70
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 70
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 69
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 68
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 68
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 68
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 68
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 67
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 67
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 67
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 66
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 66
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 66
Current issues in adjuvant treatment of stage II colon cancer 65
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 64
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 63
Improved therapeutic index of cisplatin with procaine HCl 63
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 61
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 61
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 61
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 56
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 56
The medical treatment of advanced colorectal 56
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 54
Role of oxaliplatin in the treatment of colorectal neoplasms 52
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 50
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 49
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 48
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 47
The clinical management of early and advanced colorectal cancer 44
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 44
LE ANEMIE 43
Clinical aspects of drug resistance 41
Biochemical determinants of antineoplastic activity of fluoropyrimidines 41
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 40
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 40
The neo-adjuvant, surgical and adjuvant treatment of gastric 39
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 39
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 38
Adjuvant treatment of colorectal cancer in the elderly 37
PROTOCOLLI DI CHEMIOTERAPIA ANTINEOPLASTICA 35
Effects of high dose methotrexate and leucovorin on murine haemopoietic stem cells 35
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 34
Randomized comparison of. weekly bolus five-fluorouracil with or without leucovorin in metastatic colorectal carcinoma 34
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 33
Last news from ASCO 2000 in the topic of colorectal cancer 33
Talking Tomudex: introduction 32
Superiority of twice daily vs once daily oral methylprednisolone in combination with ondansetron in the prevention of delayed emesis due to moderately and highly emetogenic chemotherapy. 32
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 32
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 32
Methotrexate resistant cells as target for selective chemotherapy 31
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 31
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 31
Rapid development of resistance to antifolates in vitro: possible clinical implications 31
Totale 6.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019642 0 0 0 0 0 0 0 0 0 0 373 269
2019/20202.750 161 191 95 398 197 447 267 333 198 242 47 174
2020/20211.509 25 185 33 204 42 185 71 207 293 45 173 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024138 29 8 3 3 16 24 1 11 43 0 0 0
Totale 7.383